News >

FDA Grants Adjuvant Dabrafenib/Trametinib Breakthrough Designation for BRAF+ Melanoma

Jason Harris
Published: Monday, Oct 23, 2017

Samit Hirawat, executive vice president and head, Global Drug Development at Novartis Oncology

Samit Hirawat
The FDA has awarded the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) a breakthrough therapy designation for the adjuvant treatment of patients with stage III melanoma with a BRAF V600 mutation following complete resection.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Community Practice Connections™: 15th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20202.0
Publication Bottom Border
Border Publication
x